Amazon (NASDAQ: AMZN | AMZN Price Prediction) just made a quiet move that could reshape how Americans access weight-loss drugs. On April 9, 2026, it announced that its pharmacy unit will stock new GLP-1 weight-loss pill Foundayo at One Medical kiosks and offer same-day home delivery, with plans to expand that access to 4,500 locales by end of 2026. Several companies stand to benefit from this distribution expansion, but their exposure varies considerably.
Five Companies Positioned for the GLP-1 Distribution Boom
Eli Lilly (NYSE: LLY) makes Foundayo and its injectable counterpart Zepbound (tirzepatide). Lilly sells directly to patients through LillyDirect, and Amazon Pharmacy now serves as a key dispensing partner for that channel. Lilly began selling Foundayo directly to cash-pay customers through LillyDirect at $149 per month for the lowest dose.
CVS Health (NYSE: CVS) operates retail pharmacies, the Caremark pharmacy benefit manager, and Aetna insurance. All three arms touch GLP-1 distribution. Caremark decides formulary status, and CVS retail fills prescriptions.
Novo Nordisk (NYSE: NVO) makes Wegovy and Ozempic, Lilly’s primary competitors in the GLP-1 space. Amazon Pharmacy has been stocking Novo’s Wegovy pill at its kiosks since January, so Novo already has a foothold in this channel, though Lilly’s Foundayo now joins it.
Viking Therapeutics (NASDAQ: VKTX) is developing VK2735, a dual GLP-1/GIP agonist with the same mechanism as Zepbound. It has no approved products yet, but every headline validating the GLP-1 market strengthens the investment case for its pipeline.
How Each Business Is Positioned
Lilly has the most direct exposure. Zepbound generated $4.26 billion in Q4 2025 revenue, up 123% year-over-year. Combined with Mounjaro’s $7.41 billion, the two drugs produced $11.67 billion in a single quarter. Because Amazon Pharmacy is now a dispensing arm for LillyDirect, every prescription filled through that channel flows directly to Lilly’s top line. Lilly’s full-year 2025 revenue reached $65.18 billion, up 44.7% year-over-year, and management guided for $80 billion to $83 billion in 2026 revenue.
Amazon benefits differently. Pharmacy is part of a broader retail and consumer health strategy. Amazon Pharmacy began delivering GLP-1 medications in 2021 and has steadily expanded the service. Same-day delivery now reaches nearly 100 million customers. Foundayo, as a pill requiring no refrigeration, fits the kiosk model. Amazon invested over $4 billion in 2025 to triple its companywide delivery options. The pharmacy business builds Prime stickiness and positions Amazon deeper in healthcare.
CVS operates across the entire GLP-1 supply chain. Caremark processes insurance claims, retail pharmacies fill scripts, and Aetna covers many patients. Same-store prescription volume at CVS grew 9.7% in Q4 2025, an accelerating trend reflecting rising GLP-1 adoption. Pharmacy sub-segment revenue grew 15.2% in Q4 2025 to $31.38 billion. Amazon Pharmacy competes with CVS retail, but Caremark still processes many insurance claims behind the scenes.
Novo Nordisk faces the most competitive pressure. Novo’s U.S. operations declined 15% in Q4 2025 due to lower realized prices and market share losses. The company issued 2026 guidance calling for adjusted sales growth of −5% to −13% at constant exchange rates. Adding Lilly’s Foundayo to the same Amazon kiosks where Wegovy already sits intensifies head-to-head competition.
Viking lacks both approved products and an Amazon Pharmacy relationship. Its lead asset, VK2735, is in Phase 3 trials with over 4,500 patients enrolled. The company benefits indirectly: the more patients who start GLP-1 therapy through accessible channels like Amazon Pharmacy, the larger the eventual market for VK2735 if approved.
What Management Is Saying
Eli Lilly CEO David Ricks: “Entering our 150th year with a deep pipeline and platforms like LillyDirect, we’re positioned to reach more patients than ever and expand our global health impact.”
Amazon CEO Andy Jassy: “With such strong demand for our existing offerings and seminal opportunities like AI, chips, robotics, and low earth orbit satellites, we expect to invest about $200 billion in capital expenditures across Amazon in 2026.” Pharmacy sits within that broader investment thesis around reaching customers faster and more directly.
CVS CEO David Joyner: “From lowering drug prices, to improving navigation of health care, to being the front door of care across our country, we are well positioned to achieve our ambition to be the most trusted health care company in America.”
Novo Nordisk President Mike Doustdar: “In 2026, Novo Nordisk will face pricing headwinds in an increasingly competitive market. However, we are very encouraged by the promising early uptake from the US launch of Wegovy pill.” Lilly and Amazon project expansive growth ambitions, while Novo Nordisk strikes a more cautious tone on pricing and competition.
Viking CEO Brian Lian: “The past year was an exceptional year for Viking marked by rapid progress across our obesity portfolio.” Lian is focused on clinical milestones, not commercial distribution, appropriate for a pre-revenue company.
Who Actually Benefits Most
Lilly is the clearest winner. As mentioned, Amazon Pharmacy is a direct dispensing channel for LillyDirect, meaning Foundayo prescriptions written through Lilly’s platform and fulfilled by Amazon flow straight to Lilly’s revenue. Lilly’s manufacturing expansion, including a $6 billion facility in Alabama and a $3 billion oral medicine facility in Europe, supports that scale. The pill format removes the cold-chain barrier that kept injectable GLP-1s off kiosk shelves.
Amazon benefits meaningfully too. Every Foundayo prescription deepens the healthcare relationship with Prime members, adds recurring revenue, and validates the One Medical kiosk model for future drug categories. CVS benefits from accelerating prescription volume even as Amazon competes for retail share because Caremark’s PBM role keeps it embedded in the claims process. Novo faces the most competitive pressure as Lilly’s pill joins Wegovy in the same Amazon kiosks. Viking remains a longer-term story, with Phase 3 data expected to define its commercial opportunity.
The Bottom Line
The GLP-1 distribution race is expanding beyond traditional pharmacies. Lilly benefits most directly, with Amazon a strong secondary winner. CVS retains its integrated role, Novo faces rising competitive pressure, and Viking watches from the sidelines. Watch Lilly’s manufacturing capacity and Amazon’s kiosk expansion pace as key signals going forward.
Top Gaining Stocks
Top Losing Stocks